MarketCap
Facebook
X
TelegramObsEva SA EPS Ratio 2011-2026 | OBSV
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio ObsEva SA
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | -1.67 | -2.49 | -1.91 | -2.25 | -1.4 | -1.87 | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -1.4 | -2.49 | -1.93 |
Quarterly EPS Ratio ObsEva SA
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.8 | - | - | - | -0.49 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -0.49 | -0.8 | -0.645 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Biotechnology industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
ADC Therapeutics SA
ADCT
|
-3.77 | $ 3.78 | - | $ 105 M |  Schweiz |
 |
MorphoSys AG
MOR
|
-15.4 | - | 2.43 % | $ 254 M |  Germany |
 |
Akebia Therapeutics
AKBA
|
-0.02 | $ 1.35 | -2.17 % | $ 347 M |  USA |
 |
Akari Therapeutics, Plc
AKTX
|
-0.09 | $ 3.5 | -21.7 % | $ 236 B |  Britain |
 |
Aldeyra Therapeutics
ALDX
|
-0.56 | $ 1.58 | -4.82 % | $ 94.9 M | USA |
 |
Aligos Therapeutics
ALGS
|
-2.45 | $ 8.36 | 4.89 % | $ 82.6 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
2.39 | $ 330.71 | 3.72 % | $ 43.3 B | USA |
 |
Altimmune
ALT
|
-1 | $ 3.47 | 3.89 % | $ 306 M | USA |
 |
ALX Oncology Holdings
ALXO
|
-1.9 | $ 1.98 | 0.25 % | $ 106 M | USA |
 |
Amgen
AMGN
|
14.3 | $ 346.45 | -0.43 % | $ 186 B | USA |
 |
I-Mab
IMAB
|
-7.66 | - | - | $ 866 M |  China |
 |
Amneal Pharmaceuticals
AMRX
|
0.23 | $ 12.37 | -0.92 % | $ 3.88 B | USA |
 |
Genfit SA
GNFT
|
1.51 | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-0.26 | - | -13.47 % | $ 169 M | France |
 |
Anika Therapeutics
ANIK
|
-5.64 | $ 15.0 | 1.32 % | $ 220 M | USA |
 |
ANI Pharmaceuticals
ANIP
|
-1.04 | $ 76.34 | 2.87 % | $ 1.47 B | USA |
 |
Annexon
ANNX
|
-1.34 | $ 5.64 | 2.45 % | $ 875 M | USA |
 |
Aptorum Group Limited
APM
|
-0.78 | $ 0.92 | -1.11 % | $ 5.02 M | China |
 |
Midatech Pharma plc
MTP
|
-31 | - | -18.52 % | $ 27.3 M | Britain |
 |
Aprea Therapeutics
APRE
|
-1.93 | $ 0.73 | 2.63 % | $ 4.77 M | USA |
 |
Aquestive Therapeutics
AQST
|
-0.78 | $ 4.15 | 0.48 % | $ 444 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
-2.4 | $ 8.43 | 4.98 % | $ 231 M |  Israel |
 |
Ardelyx
ARDX
|
-0.26 | $ 6.08 | 2.27 % | $ 1.47 B | USA |
 |
argenx SE
ARGX
|
-7.99 | $ 752.05 | 0.75 % | $ 25 B |  Niderland |
 |
Acorda Therapeutics
ACOR
|
-204 | - | -24.86 % | $ 820 K | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-0.13 | $ 23.93 | 1.27 % | $ 3.04 B | USA |
 |
Arvinas
ARVN
|
-1.14 | $ 11.11 | 2.4 % | $ 788 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-6.62 | - | - | $ 86.2 M | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
-0.01 | $ 61.57 | 0.88 % | $ 8.24 B | USA |
 |
Advaxis
ADXS
|
-7.99 | - | -9.65 % | $ 45.9 M | USA |
 |
Applied Molecular Transport
AMTI
|
-3.25 | - | - | $ 10.1 M | USA |
 |
Assembly Biosciences
ASMB
|
-0.55 | $ 30.01 | 3.43 % | $ 336 M | USA |
 |
Aeterna Zentaris
AEZS
|
-0.07 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-1.91 | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
-1.57 | - | 1.93 % | $ 17.4 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-24.9 | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-0.36 | - | - | $ 26.5 M | USA |
 |
Akero Therapeutics
AKRO
|
-3.75 | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-2.52 | - | 0.23 % | $ 488 M | USA |
 |
Actinium Pharmaceuticals
ATNM
|
-1.09 | $ 1.14 | 16.28 % | $ 35.6 M | USA |
 |
Atossa Therapeutics
ATOS
|
-4.04 | $ 5.21 | -2.89 % | $ 44.9 M | USA |
 |
Atara Biotherapeutics
ATRA
|
2.61 | $ 5.03 | 0.7 % | $ 63.1 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-0.72 | - | 3.16 % | $ 1.9 M | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
1.6 | $ 16.04 | 2.75 % | $ 2.16 B | Canada |
 |
Autolus Therapeutics plc
AUTL
|
-1.08 | $ 1.42 | 0.35 % | $ 378 M | Britain |
 |
Alpine Immune Sciences
ALPN
|
-1.73 | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
-1.96 | - | 10.36 % | $ 9.8 M | USA |